These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38244749)

  • 21. [Transmission-blocking vaccine candidate of Plasmodium vivax Pvs25 is highly conservative among Chinese isolates].
    Zheng L; Xu WM; Liu YJ; Yang YM; Cao YM
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2004 Feb; 22(1):16-9. PubMed ID: 15283259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasmodium vivax CSP-Pvs25 variants from southern Mexico produce distinct patterns of infectivity for Anopheles albimanus versus An. pseudopunctipennis, in each case independent of geographical origin.
    González-Cerón L; Rodríguez MH; Nettel-Cruz JA; Hernández-Ávila JE; Malo-García IR; Santillán-Valenzuela F; Villarreal-Treviño C
    Parasit Vectors; 2019 Feb; 12(1):86. PubMed ID: 30786915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restricted genetic heterogeneity of the Plasmodium vivax transmission-blocking vaccine (TBV) candidate Pvs48/45 in a low transmission setting: Implications for the Plasmodium vivax malaria vaccine development.
    Asali S; Raz A; Turki H; Mafakher L; Razmjou E; Solaymani-Mohammadi S
    Infect Genet Evol; 2021 Apr; 89():104710. PubMed ID: 33421653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of PvLAP5 and Pvs25 qRT-PCR assays for the detection of Plasmodium vivax gametocytes in field samples preserved at ambient temperature from remote malaria endemic regions of Panama.
    Obaldía N; Barahona I; Lasso J; Avila M; Quijada M; Nuñez M; Marti M
    PLoS Negl Trop Dis; 2022 Apr; 16(4):e0010327. PubMed ID: 35394999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Blagborough AM; Musiychuk K; Bi H; Jones RM; Chichester JA; Streatfield S; Sala KA; Zakutansky SE; Upton LM; Sinden RE; Brian I; Biswas S; Sattabonkot J; Yusibov V
    Vaccine; 2016 Jun; 34(28):3252-9. PubMed ID: 27177945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Very high carriage of gametocytes in asymptomatic low-density Plasmodium falciparum and P. vivax infections in western Thailand.
    Nguitragool W; Mueller I; Kumpitak C; Saeseu T; Bantuchai S; Yorsaeng R; Yimsamran S; Maneeboonyang W; Sa-Angchai P; Chaimungkun W; Rukmanee P; Puangsa-Art S; Thanyavanich N; Koepfli C; Felger I; Sattabongkot J; Singhasivanon P
    Parasit Vectors; 2017 Oct; 10(1):512. PubMed ID: 29065910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmodium vivax malaria vaccine development.
    Arévalo-Herrera M; Herrera S
    Mol Immunol; 2001 Dec; 38(6):443-55. PubMed ID: 11741694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation, crystallization and preliminary X-ray analysis of a complex between the Plasmodium vivax sexual stage 25 kDa protein Pvs25 and a malaria transmission-blocking antibody Fab fragment.
    Saxena AK; Singh K; Long CA; Garboczi DN
    Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):2054-7. PubMed ID: 15502325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic diversity in the transmission-blocking vaccine candidate Plasmodium vivax gametocyte protein Pvs230 from the China-Myanmar border area and central Myanmar.
    Zhao X; Hu Y; Zhao Y; Wang L; Wu Z; Soe MT; Kyaw MP; Cui L; Zhu X; Cao Y
    Parasit Vectors; 2022 Oct; 15(1):371. PubMed ID: 36253843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization.
    Miyata T; Harakuni T; Tsuboi T; Sattabongkot J; Kohama H; Tachibana M; Matsuzaki G; Torii M; Arakawa T
    Infect Immun; 2010 Sep; 78(9):3773-82. PubMed ID: 20584978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.
    Cao Y; Hayashi CTH; Kumar N
    J Infect Dis; 2024 Jun; 229(6):1894-1903. PubMed ID: 38408353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural diversity, natural selection and intragenic recombination in the Plasmodium vivax merozoite surface protein 9 locus in Thailand.
    Songsaigath S; Putaporntip C; Kuamsab N; Jongwutiwes S
    Infect Genet Evol; 2020 Nov; 85():104467. PubMed ID: 32711079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploration of genetic diversity of Plasmodium vivax circumsporozoite protein (Pvcsp) and Plasmodium vivax sexual stage antigen (Pvs25) among North Indian isolates.
    Kaur H; Sehgal R; Kumar A; Sehgal A; Bharti PK; Bansal D; Mohapatra PK; Mahanta J; Sultan AA
    Malar J; 2019 Sep; 18(1):308. PubMed ID: 31492135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Worldwide population genetic analysis and natural selection in the Plasmodium vivax Generative Cell Specific 1 (PvGCS1) as a transmission-blocking vaccine candidate.
    Mehrizi AA; Dodangeh F; Zakeri S; Djadid ND
    Infect Genet Evol; 2016 Sep; 43():50-7. PubMed ID: 27180894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Plasmodium vivax isolates in Thailand using polymorphic markers Plasmodium merozoite surface protein (PvMSP) 1 and PvMSP3.
    Suphakhonchuwong N; Chaijaroenkul W; Rungsihirunrat K; Na-Bangchang K; Kuesap J
    Parasitol Res; 2018 Dec; 117(12):3965-3978. PubMed ID: 30306265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Multi-Stage
    McCaffery JN; Fonseca JA; Singh B; Cabrera-Mora M; Bohannon C; Jacob J; Arévalo-Herrera M; Moreno A
    Front Cell Infect Microbiol; 2019; 9():135. PubMed ID: 31119106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly efficient protein expression of Plasmodium vivax surface antigen, Pvs25, by silkworm and its biochemical analysis.
    Miyata T; Minamihata K; Kurihara K; Kamizuru Y; Gotanda M; Obayashi M; Kitagawa T; Sato K; Kimura M; Oyama K; Ikeda Y; Tamaki Y; Lee JM; Sakao K; Hamanaka D; Kusakabe T; Tachibana M; Ibrahim HR
    Protein Expr Purif; 2022 Aug; 195-196():106096. PubMed ID: 35460871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes.
    Arakawa T; Tsuboi T; Kishimoto A; Sattabongkot J; Suwanabun N; Rungruang T; Matsumoto Y; Tsuji N; Hisaeda H; Stowers A; Shimabukuro I; Sato Y; Torii M
    Vaccine; 2003 Jul; 21(23):3143-8. PubMed ID: 12804841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.